Press release
Myelofibrosis (MF) Market Poised for 3.2 % Growth, Set to Hit $1.76 Billion by 2029
Myelofibrosis (MF)
The growing demand for targeted therapies is expected to drive the growth of the myelofibrosis (MF) market in the coming years. Targeted therapies are designed to tailor treatments based on individual genetic, environmental, and lifestyle factors, making them more precise and effective. Advancements in genomics, biotechnology, and data analytics are enabling the development of treatments that address key molecular pathways, such as JAK-STAT signaling in myelofibrosis. This has led to the emergence of JAK inhibitors like Ruxolitinib, Fedratinib, and Pacritinib, which help manage symptoms and slow disease progression in myelofibrosis patients. For example, in April 2024, the American Society of Gene & Cell Therapy reported an 11% increase in Phase I therapies, indicating significant growth in the pipeline of targeted therapies. Therefore, the rising demand for targeted therapies is expected to contribute to the growth of the myelofibrosis (MF) market.
Get Your Myelofibrosis (MF) Market Report Here:
https://www.thebusinessresearchcompany.com/report/myelofibrosis-mf-global-market-report
What is the future CAGR of the myelofibrosis (mf) market, and how will it impact industry expansion?
The myelofibrosis (MF) market has grown steadily, increasing from $1.50 billion in 2024 to $1.55 billion in 2025 at a CAGR of 3.5%. Growth has been driven by a rising prevalence of myeloproliferative neoplasms, increased awareness and early diagnosis, a growing adoption of JAK inhibitors, expanding access to bone marrow transplants, and increasing regulatory approvals for new therapies.
The myelofibrosis (MF) market is projected to witness steady growth, reaching $1.76 billion by 2029 at a CAGR of 3.2%. Growth in this market is driven by increasing demand for personalized treatment plans, expanding clinical trials for gene and cell therapy, rising use of combination treatments, improved healthcare coverage for rare diseases, and greater investments in hematology research. Notable trends in this period include advancements in gene-editing technologies, the development of fibrosis-targeting drugs, next-generation JAK inhibitors, a growing interest in immunotherapy for myelofibrosis, and AI-driven drug discovery.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21226&type=smp
What are the most significant trends transforming the myelofibrosis (mf) market today?
In the myelofibrosis (MF) market, companies are expanding targeted therapies like JAK1/JAK2 and ACVR1 inhibitors to enhance treatment efficacy and improve patient outcomes. For instance, in September 2023, GSK plc, a UK-based pharmaceutical company, received FDA approval for Ojjaara (momelotinib), a dual-target therapy for intermediate- or high-risk myelofibrosis. It targets both JAK1/JAK2 and ACVR1 pathways, addressing inflammation and abnormal blood cell production while improving hemoglobin levels and reducing transfusion dependency. This approval offers a new standard in MF management, particularly for patients suffering from anemia, a major unmet need in the disease landscape.
Which key market segments comprise the myelofibrosis (mf) market and drive its revenue growth?
The myelofibrosis (MF) market covered in this report is segmented -
1) By Drug Type: Jak Inhibitor, Immunomodulators, Hydroxyurea, Other Drug Types
2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Jak Inhibitor: Ruxolitinib, Fedratinib, Momelotinib, Itacitinib
2) By Immunomodulators: Thalidomide, Lenalidomide, Pomalidomide
3) By Hydroxyurea: Oral Hydroxyurea, Injectable Hydroxyurea
4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs), Danazol, Monoclonal Antibodies, Chemotherapy Agents
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21226
What regions are at the forefront of myelofibrosis (mf) market expansion?
North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (MF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the leading players fueling growth in the myelofibrosis (mf) market?
Major companies operating in the myelofibrosis (MF) market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., A. Menarini Industrie Farmaceutiche Riunite S.r.l., Incyte Corporation, Sobi Inc., MorphoSys AG, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceutical Co. Ltd., NS Pharma Inc., Impact Biomedicines Inc., Kartos Therapeutics Inc., Geron Corporation
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21226&type=smp
What Is Covered In The Myelofibrosis (MF) Global Market Report?
•Market Size Forecast: Examine the myelofibrosis (mf) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the myelofibrosis (mf) market for a structured understanding.
•Key Players Overview: Analyze major players in the myelofibrosis (mf) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the myelofibrosis (mf) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the myelofibrosis (mf) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the myelofibrosis (mf) market.
•Industry Challenges: Identify potential risks and obstacles affecting the myelofibrosis (mf) market.
•Competitive Landscape: Review strategic developments in the myelofibrosis (mf) market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelofibrosis (MF) Market Poised for 3.2 % Growth, Set to Hit $1.76 Billion by 2029 here
News-ID: 3934286 • Views: …
More Releases from The Business Research Company
Emerging Markets And Increasing Disposable Income Fueling Diamond Market Growth: …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Diamond Market Through 2025?
In the past few years, there has been a stable expansion in the diamond market size. The prediction is it will increase from $1.33 billion in 2024 to $1.39 billion in 2025, boasting a compound annual growth rate…
2025-2034 Nonmetallic Minerals Mining Support Activities Market Outlook: Key Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Nonmetallic Minerals Mining Support Activities Industry Market Size Be by 2025?
In the past few years, there has been a robust expansion in the size of the nonmetallic minerals mining support activities market. It is projected to escalate from $34.04 billion in 2024 to $36.55 billion…
Professional Street Sweeper Industry Outlook 2025-2029: Market Set to Cross $3.1 …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Professional Street Sweeper Market Size By 2025?
The market size of professional street sweepers has seen significant expansion in the past few years. The market, predicted to rise from $2.37 billion in 2024 to $2.5 billion in 2025, boasts a compound annual growth rate (CAGR)…
Key Trends Reshaping the Industrial Wet Dust Collector Market: Advanced Filtrati …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Industrial Wet Dust Collector Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a robust growth in the size of the industrial wet dust collector market. It is expected to swell from $1.89 billion in 2024 to $2 billion by 2025, showing a…
More Releases for JAK
Key Trends Influencing the Growth of the Janus Kinase (JAK) Inhibitors Market in …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Janus Kinase (JAK) Inhibitors Market Through 2025?
The market size of Janus Kinase (JAK) inhibitors has experienced a quick growth over the recent years. The market, which stood at $20.19 billion in 2024, is projected to see a rise to $23.56 billion…
Vitiligo Treatment Innovation Accelerates with JAK Inhibitors and Novel Immunoth …
Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving the Vitiligo treatment landscape. Let's explore how this will impact the Vitiligo treatment landscape.
DelveInsight's "Vitiligo Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights on the vitiligo pipeline, showcasing a dynamic landscape of emerging therapies and a promising outlook for patients suffering from this challenging autoimmune skin…
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing…
Leading Growth Driver in the Janus Kinase (JAK) Inhibitors Market in 2025: Surgi …
Which drivers are expected to have the greatest impact on the over the janus kinase (jak) inhibitors market's growth?
The escalating occurrences of autoimmune disorders are anticipated to stimulate the expansion of the Janus kinase (JAK) inhibitors market. These disorders involve a broad spectrum of abnormalities within the immune system where it erroneously attacks and destroys healthy cells, tissues, and organs. The therapeutic benefits of Janus Kinase (JAK) inhibitors for autoimmune…
Janus Kinase (JAK) Inhibitor Pipeline Therapeutics Assessment Report 2024 (Updat …
DelveInsight's, "Janus Kinase Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Janus Kinase…
Janus kinase (JAK) Inhibitors Competitive Landscape Report 2024
DelveInsight's, "Janus kinase inhibitors Competitive landscape 2024" report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Janus kinase Inhibitors Report
• DelveInsight's Janus kinase Inhibitors report depicts a robust space…
